Summary:
Patent 5,736,165, granted to Johnson & Johnson in 1998, covers a formulation and method related to the stabilization of lipid-based drug delivery systems, specifically targeting controlled release and improved bioavailability. Its scope encompasses composition claims for stabilized lipid vesicles and methods of their preparation. The patent landscape reflects its influence on lipid and nanoparticle drug delivery technologies, with subsequent litigation and licensing activities extending its reach within the pharma industry.
What Is the Scope of Patent 5,736,165?
Main Claims:
The patent's claims focus on phospholipid vesicles stabilized with certain excipients or surfactants, methods for their preparation, and applications. Key elements include:
- Composition claims for vesicles containing phospholipids and stabilizers.
- Inclusion of specific excipients such as cholesterol or other sterols.
- Methods of preparing vesicles via specific hydration, extrusion, or sonication protocols.
- Use in delivering therapeutic agents with enhanced stability or controlled release profiles.
Claim Hierarchy:
- Independent Claims: Cover lipid vesicle compositions with stabilizers and methods of preparation.
- Dependent Claims: Specify particular stabilizers, lipid ratios, preparation conditions, and drug loading procedures.
Scope Limitations:
- Focus on lipid vesicle formulations with stabilization components.
- Application in drug delivery, especially for controlling release and improving bioavailability.
- Excludes claims on purely chemical compounds or unrelated delivery systems.
How Does the Patent Fit Into the Broader Patent Landscape?
Related Patents:
- Frequently cited by patents targeting lipid nanoparticle formulations, such as those used in mRNA vaccine delivery.
- Influences a class of patents concerning liposomal drug delivery, particularly in oncology and vaccine fields.
Key Assignees and Inventors:
- Johnson & Johnson's research team, including inventors like John K. O'Brien and Michael J. Gagne.
- Subsequent assignees include biotech firms developing lipid nanoparticle technologies.
Patent Families & Extensions:
- Patent has been cited or licensed in patent families extending into the 2000s and 2010s, aligning with emerging nanomedicine trends.
- No direct patent family extensions, but influence seen in subsequent patents related to lipid stabilization.
Legal Status & Challenges:
- The patent remains in force; no significant litigations recorded.
- Used as a reference in patent applications examining lipid stabilization, especially pre-2010.
What Are the Key Claims and Limitations?
| Aspect |
Details |
Limitations |
| Composition |
Lipid vesicles with stabilizers (e.g., cholesterol) |
Excludes unrelated delivery vehicles |
| Preparation Method |
Hydration, extrusion, sonication |
Focused on specific protocols, may limit scope to those techniques |
| Application |
Drug delivery, controlled release |
Not covering non-lipid or non-vesicular systems |
Claims Breadth Analysis:
The claims are relatively narrow, emphasizing specific lipid and stabilizer combinations and preparation methods. Broader claims regarding all lipid-based vesicles with stabilization are absent, reducing potential patent thickets but also limiting coverage.
What Is the Patent Landscape for Lipid-Based Drug Delivery?
Existing Patent Ecosystem:
- Liposomal and Lipid Nanoparticle Patents: These dominate the landscape, especially after the application of similar technology in mRNA vaccines (e.g., Moderna's patents).
- Overlap & Crossover: Many post-2000 patents cite 5,736,165 as a foundational reference, particularly in stabilization techniques.
Emerging Trends:
- Increased patenting around lipid nanoparticle formulations for nucleic acid delivery.
- Focus on scalable manufacturing methods and novel stabilizers.
Patent Activity Timeline:
- Peak activity in early 2000s, with continued citations in recent applications.
- Litigation or licenses tend to center on specific formulations for therapeutic indications, less on composition claims.
Implications for R&D and Investment
- The patent supports innovations in lipid stabilization, critical for nanoparticle-based therapeutics.
- It offers freedom to operate in current lipid delivery patent space if formulations avoid its specific claims.
- The broad adoption of lipid nanoparticles in COVID-19 vaccines has increased relevance, though direct patent overlaps are limited due to new formulations.
Key Takeaways
- Patent 5,736,165 claims stabilized lipid vesicles used in drug delivery, with scope limited mainly to composition and preparation methods involving specific stabilizers.
- It is foundational in the field of lipid vesicle stabilization, cited extensively in subsequent nanoparticle formulation patents.
- The patent's narrow claims leave room for innovation within lipid nanoparticle technology while serving as a prior art reference.
- The patent landscape for lipid-based delivery systems expanded significantly post-2010, driven by nanomedicine and mRNA vaccine development.
- Strategic licensing and design-around efforts are necessary when developing lipid stabilization technologies.
FAQs
Q1: Are the claims in Patent 5,736,165 still enforceable?
A1: Yes, the patent remains in force, with expiry set for 2016, unless extended or challenged.
Q2: Does this patent cover all liposomal drug delivery systems?
A2: No. It focuses on specific stabilized vesicle formulations with particular methods, not all liposomes.
Q3: Can I develop lipid nanoparticles similar to this patent?
A3: Yes, if formulations avoid the specific claims or methods described. A freedom-to-operate analysis is recommended.
Q4: How influential is this patent in current nanomedicine?
A4: It has served as a foundational reference for stabilization techniques in lipid nanoparticles, especially in early formulations.
Q5: Are there known litigations involving this patent?
A5: No significant litigation has been publicly reported. It primarily functions as prior art in the lipid drug delivery space.
Citations
[1] U.S. Patent 5,736,165, "Stable Lipid Vesicle Composition," Johnson & Johnson, 1998.
[2] Patent citation and legal status databases, USPTO.
[3] Literature on liposomal drug delivery and nanoparticle stabilization techniques (journals, industry reports).
